Cargando…

Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1

Failure of colorectal cancer (CRC) treatment is due to residual disease, and its timely identification is critical for patient survival. Detecting CRC‐associated mutations in patient circulating cell‐free DNA is confounded by tumor mutation heterogeneity, requiring primary tumor sequencing to identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Symonds, Erin L., Pedersen, Susanne K., Yeo, Bernita, Al Naji, Hiba, Byrne, Susan E., Roy, Amitesh, Young, Graeme P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120880/ https://www.ncbi.nlm.nih.gov/pubmed/35000264 http://dx.doi.org/10.1002/1878-0261.13178

Ejemplares similares

Methylation and Gene Expression of BCAT1 and IKZF1 in Colorectal Cancer Tissues
por: Jedi, Maher, et al.
Publicado: (2018)

Detection of methylated BCAT1 and IKZF1 after curative‐intent treatment as a prognostic indicator for colorectal cancer recurrence
por: Pedersen, Susanne K., et al.
Publicado: (2022)

Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia
por: Pedersen, Susanne K., et al.
Publicado: (2015)

A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia
por: Symonds, Erin L, et al.
Publicado: (2016)

A cross‐sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor‐derived DNA with CEA for detection of recurrent colorectal cancer
por: Young, Graeme P., et al.
Publicado: (2016)

Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer
por: Young, Graeme P., et al.
Publicado: (2021)

Lenalidomide induces degradation of IKZF1 and IKZF3
por: Krönke, Jan, et al.
Publicado: (2014)

Ruscogenin Alleviates Myocardial Ischemia-Induced Ferroptosis through the Activation of BCAT1/BCAT2
por: Fu, Fei, et al.
Publicado: (2022)

Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3
por: Liu, Xiao-Ping, et al.
Publicado: (2018)

Beyond finding druggable targets and tumor mutational burden: to measure heterogeneity by ctDNA
por: Liu, Zhichao, et al.
Publicado: (2020)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

BCAT1 promotes tumor cell migration and invasion in hepatocellular carcinoma
por: Xu, Meng, et al.
Publicado: (2016)

Data mining of the expression and regulatory role of BCAT1 in hepatocellular carcinoma
por: Zou, Haifan, et al.
Publicado: (2019)

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
por: Stecklein, Shane R., et al.
Publicado: (2023)

Impaired expression of BCAT1 relates to muscle atrophy of mouse model of sarcopenia
por: Ouyang, Hui, et al.
Publicado: (2022)

Reciprocal control of lncRNA-BCAT1 and β-catenin pathway reveals lncRNA-BCAT1 long non-coding RNA acts as a tumor suppressor in colorectal cancer
por: Xie, Fei, et al.
Publicado: (2017)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide
por: Abdulkarim, Haya, et al.
Publicado: (2020)

IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma
por: Liu, Meng, et al.
Publicado: (2022)

P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways
por: He, Xiaoxiao, et al.
Publicado: (2022)

The clinical impact of IKZF1 mutation in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2023)

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models
por: Sauer, Carolin M, et al.
Publicado: (2022)

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2020)

BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases
por: Papathanassiu, Adonia E., et al.
Publicado: (2017)

BCAT1 affects mitochondrial metabolism independently of leucine transamination in activated human macrophages
por: Ko, Jeong-Hun, et al.
Publicado: (2020)

BCAT1 promotes osteoclast maturation by regulating branched-chain amino acid metabolism
por: Go, Miyeon, et al.
Publicado: (2022)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)
por: Cai, Chunyan, et al.
Publicado: (2018)

Circulating epigenetic biomarkers for detection of recurrent colorectal cancer
por: Symonds, Erin L., et al.
Publicado: (2020)

Detection of ctDNA in the plasma of patients with papillary thyroid carcinoma
por: Li, Huiqiang, et al.
Publicado: (2019)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Current status of ctDNA in precision oncology for hepatocellular carcinoma
por: Li, Yan, et al.
Publicado: (2021)

The potential, analysis and prospect of ctDNA sequencing in hepatocellular carcinoma
por: Ding, Yubo, et al.
Publicado: (2022)

Current and Future Clinical Applications of ctDNA in Immuno-Oncology
por: Stadler, Julia-Christina, et al.
Publicado: (2022)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rgs1vi76f995h77919jn7g4nmq